* Product order of MSEK 41 to be delivered in H1 2027 * Positive EBIT despite low product sales * We...
Gofore’s Q3 sales and adjusted EBITA came in slightly below our estimates.
Aspo was not able to sell ESL Shipping at a reasonable price, and so both segments will be listed as...
Redeye lowers its Base Case to SEK99 (102), as a higher risk-free rate offsets EBITA estimates raise...
* We take a closer look at recent regulatory trends and tenders * Benchmark vs.
Redeye comments on VEF’s Q3 2026 report and Brazil’s presidential election.
Hyresintäkterna låg i nivå med föregående år på 46,1 meur för årets första nio månader.
Omsättningen steg 6% till 6 250 mkr för årets första nio månader och justerad ebitamarginal nådde 16...
Redeye presents its preview of RaySearch's Q3 2026 results due on November 3.
BioInvent presented the complete Part B cohort of BI-1808 plus pembrolizumab in platinum-resistant o...
Redeye updates on Evolution after Q3-results which were in line with our expectations.
Ependion's Q3 report confirms that the recovery is gaining momentum.
* Earnings miss following soft Sweden * Estimates trimmed by 5/4% for '26e/'27e * 12x/9x '26e/'27e a...
Net sales and adjusted EBITA were slightly above LSEG Data & Analytics consensus for Q3 and the comp...
Modelon's Q3 report marked the turning point we had been waiting for: ARR returned to sequential gro...
AVTECH's Q3 net sales of SEK10.3m were 4% below our SEK10.
Gapwaves' Q3 net sales of SEK9.0m were 40% below our SEK15.
OXE Marine managed to reach EBITDA break-even in Q3, which was quite unexpected.
BB Biotech’s NAV rose 5.6% in CHF in Q3 2026 and the share price 6.
Q3 was slightly ahead of our forecasts, helped by transaction revenue.